Project Grant R01AI183302
Award Date
7/24/24
Completion Date
5/31/29
Dollars Obligated
$2.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanisms by which positive-sense, single-strand RNA viruses, including flaviviruses such as Dengue, Zika, and West Nile, utilize host proteins to facilitate viral replication and the formation of viral replication organelles. The $925,650 grant, awarded on June 11, 2024, will...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $760,318 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of California, Davis (UC Davis). The grant supports the development of recombinant enhanced antiviral sensors (REAVRS) to broadly inhibit virus replication and transmission, with a focus on combating zoonotic viral infections. The project entails generating and optimizing REAVR proteins, identifying...
This R01 project grant award of $699,339 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research on the transmission dynamics of dengue virus (DENV) and Zika virus (ZIKV) across a diverse landscape in northwestern coastal Ecuador. The key objectives are to:
Characterize the force of DENV infection and rate of virus introduction across 6 communities with varying remoteness (Aim 1).
Investigate how...
This $1,211,704 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to study the immune responses associated with severe disease in patients with primary dengue infection.
The key objectives are to: 1) Determine differences in innate immune responses during severe primary and secondary dengue infection; 2) Evaluate differences in dengue-specific antibodies during severe primary...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $46,715,173 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Washington University to establish the Flavivirus and Alphavirus REVAMPP (FLARE) Center. The FLARE Center will develop and optimize vaccine and antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. Key objectives include designing "plug and...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $856,769 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Texas Biomedical Research Institute, operating as the Southwest Foundation For Biomedical Research, to study the viral and host determinants of donor-specific anti-HIV/SIV immunity mediated by APOBEC3 enzymes. The research project aims to integrate diverse viral and host datasets using computational and experimental techniques...
The Cooperative Agreement award U19AI181984, funded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), will support the development of prototype vaccines and human monoclonal antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families. The $44,108,652 award will fund a collaborative project across multiple institutions to study four prototype viruses - human parainfluenza viruses,...
This $805,375 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to elucidate the tropism, receptor usage, and pathogenesis mechanisms of emerging pararubulaviruses, a group of bat-derived paramyxoviruses related to mumps virus and human parainfluenza viruses.
The research team, led by Drs. Lee and Lim, will employ innovative organ explant techniques, reverse genetics systems, and animal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to Emory University will provide $432,250 in funding from July 2024 to May 2026 to develop innovative single cell techniques and apply them to gain unprecedented insights into West Nile virus (WNV) infection of the lymphatic system and spleen. The goal is to identify the specific cellular targets of WNV infection and understand how the antiviral immune...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,072,366 to the University of Virginia to develop computational models for studying subcellular infection by diverse families of RNA viruses. The key objectives are to: 1) Compare generic and virus family-specific models for viral entry, 2) Refactor the viral replication module, and 3) Incorporate antiviral conduits between viral infection...